Aberdeen Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-203,399
Closed -$19.3M 976
2024
Q1
$19.3M Buy
203,399
+41,724
+26% +$3.87M 0.04% 410
2023
Q4
$14.4M Buy
+161,675
New +$12M 0.03% 469

Other funds holding XBI

Aberdeen Group's XBI Position: Q2 2024 in Review

Aberdeen Group sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2024, closing a stake of 203,399 shares — an estimated $19.3M sold.

Aberdeen Group first reported a position in XBI in Q4 2023 and held it in 2 quarters. The position peaked at $19.3M in Q1 2024. 761 funds tracked by Wall St. Rank hold XBI as of Q2 2024.

  • Aberdeen Group reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2024 after selling out during the quarter.
  • Aberdeen Group sold 203,399 State Street SPDR S&P Biotech ETF shares in Q2 2024, an estimated $19.3M.
  • Aberdeen Group first reported a position in State Street SPDR S&P Biotech ETF in Q4 2023 and held it in 2 quarters.
  • Aberdeen Group's State Street SPDR S&P Biotech ETF position peaked at $19.3M in Q1 2024.
  • 761 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2024.

Based on Aberdeen Group's 13F filing for Q2 2024, filed 9 Aug 2024.